|
博士生導(dǎo)師：牛瑞芳
天津醫(yī)科大學(xué)腫瘤醫(yī)院腫瘤研究所
研究員,、教授,、博士生導(dǎo)師
現(xiàn)任腫瘤研究所副所長、
公共實驗室主任
1986年畢業(yè)于南開大學(xué)生物系生物化學(xué)專業(yè)，1989年獲得南開大學(xué)生物化學(xué)碩士學(xué)位,，2012年獲得天津大學(xué)生物醫(yī)學(xué)工程博士學(xué)位。
現(xiàn)為中國抗癌協(xié)會腫瘤標(biāo)志物專業(yè)委員會委員,、中國抗癌協(xié)會分子醫(yī)學(xué)專業(yè)委員會委員,、天津市生物化學(xué)與分子生物學(xué)學(xué)會理事、天津市生物醫(yī)學(xué)工程學(xué)會組織工程專業(yè)委員會委員,，科技部重大專項和國家自然科學(xué)基金項目評審專家,，《中國腫瘤臨床》執(zhí)行編委、《中華腫瘤防治雜志》和《現(xiàn)代儀器與醫(yī)療》雜志編委,。
發(fā)表SCI收錄論文40余篇,，獲5項國家授權(quán)專利，曾獲教育部自然科學(xué)獎和天津市科技進(jìn)步獎多項,；先后承擔(dān)科技部“863”項目兩項,，國家自然科學(xué)基金國際合作項目1項，主持國家自然科學(xué)基金面上項目4項,，天津市科委重點項目2項,，天津市教委重點項目1項,。
研究方向：
- 基于蛋白質(zhì)組學(xué)和高通量測序等研究方法篩選和鑒定與腫瘤發(fā)生發(fā)展密切相關(guān)的蛋白質(zhì)，并解析相應(yīng)的信號傳導(dǎo)網(wǎng)絡(luò),。
- 聚焦腫瘤多藥耐藥的機(jī)制研究,，探索導(dǎo)致耐藥腫瘤侵襲轉(zhuǎn)移能力增強(qiáng)的分子機(jī)制，為臨床耐藥腫瘤的治療提供新思路,。
- 研究癌細(xì)胞侵襲轉(zhuǎn)移的分子機(jī)制,，解析調(diào)控癌細(xì)胞侵襲轉(zhuǎn)移的關(guān)鍵信號通路，為臨床轉(zhuǎn)移腫瘤的治療提供新靶點,。
近年來主持的研究項目：
- 國家自然科學(xué)基金面上項目（2018/01-2021/12）：TGFβ反式激活EGFR信號通路并促進(jìn)乳腺癌細(xì)胞侵襲轉(zhuǎn)移的分子機(jī)制研究（81772804,，55萬元）
- 國家自然科學(xué)基金面上項目（2014/01-2017/12）：Anxa2介導(dǎo)IL-6誘導(dǎo)的SHP2/Erk和JAK2/STAT3信號通路激活并促進(jìn)乳腺癌細(xì)胞上皮間質(zhì)轉(zhuǎn)化的分子機(jī)制研究（81372844，72萬元）
- 教育部高等學(xué)校博士學(xué)科點專項科研基金（2014/01-2016/12）：Anxa2介導(dǎo)IL-6信號通路并促進(jìn)乳腺癌細(xì)胞上皮間質(zhì)轉(zhuǎn)化的分子機(jī)制研究（20131202110002,，12萬元）
- 863計劃子課題（2012/01-2015/12）：腫瘤蛋白質(zhì)分子標(biāo)志物的研究與開發(fā)（2012AA020206,，65萬元）
- 天津市自然科學(xué)基金重點項目（2012/04-2015/03）：Anxa2調(diào)控STAT3活性和乳腺癌細(xì)胞侵襲的作用機(jī)制研究（12JCZDJC24500，20萬元）
- 國家自然科學(xué)基金面上項目（2011/01-2013/12）：MDR1與Anxa2相互作用調(diào)節(jié)耐藥乳腺癌細(xì)胞侵襲的分子機(jī)制研究（81071731,，31萬元）
- 863計劃（2008/01-2010/12）：雙親性復(fù)合靶向控釋納米藥物制劑（2007AA021802,，408萬）
近年發(fā)表SCI論文(*通訊作者)：
1. Zhao Y, Ma J, Fan Y, Wang Z, Tian R, Ji W, Zhang F*, Niu R*: TGF-beta transactivates EGFR and facilitates breast cancer migration and invasion through canonical Smad3 and ERK/Sp1 signaling pathways. Molecular oncology 2018, 12(3):305-321.
2. Yuan J, Yang Y, Gao Z, Wang Z, Ji W, Song W, Zhang F*, Niu R*: Tyr23 phosphorylation of Anxa2 enhances STAT3 activation and promotes proliferation and invasion of breast cancer cells. Breast Cancer Res Treat2017, 164(2):327-340.
3. Sun X, Zhang J, Wang Z, Ji W, Tian R, Zhang F*, Niu R*: Shp2 Plays a Critical Role in IL-6-Induced EMT in Breast Cancer Cells. International journal of molecular sciences 2017, 18(2).
4. Yang Y, Wu N, Wang Z, Zhang F, Tian R, Ji W, Ren X, Niu R*: Rack1 Mediates the Interaction of P-Glycoprotein with Anxa2 and Regulates Migration and Invasion of Multidrug-Resistant Breast Cancer Cells. International journal of molecular sciences 2016, 17(10).
5. Zhang J, Zhang F, Niu R*: Functions of Shp2 in cancer. J Cell Mol Med 2015, 19(9):2075-2083.
6. Zhang F, Wang Z, Yuan J, Wei X, Tian R, Niu R*: RNAi-mediated silencing of Anxa2 inhibits breast cancer cell proliferation by downregulating cyclin D1 in STAT3-dependent pathway. Breast Cancer Res Treat 2015, 153(2):263-275.
7. Zhang F, Wang Z, Fan Y, Xu Q, Ji W, Tian R, Niu R*: Elevated STAT3 Signaling-Mediated Upregulation of MMP-2/9 Confers Enhanced Invasion Ability in Multidrug-Resistant Breast Cancer Cells. International journal of molecular sciences 2015, 16(10):24772-24790.
8. Zhang F, Liu Y, Wang Z, Sun X, Yuan J, Wang T, Tian R, Ji W, Yu M, ZhaoY,Niu R*: A novel Anxa2-interacting protein Ebp1 inhibits cancer proliferation and invasion by suppressing Anxa2 protein level. Mol Cell Endocrinol 2015, 411:75-85.
9. Zhang F, Zhang H, Wang Z, Yu M, Tian R, Ji W, Yang Y, Niu R*: P-glycoprotein associates with Anxa2 and promotes invasion in multidrug resistant breast cancer cells. Biochem Pharmacol 2014, 87(2):292-302.
10. Wu B, Zhang F, Yu M, Zhao P, Ji W, Zhang H, Han J, Niu R*: Up-regulation of Anxa2 gene promotes proliferation and invasion of breast cancer MCF-7 cells. Cell proliferation 2012, 45(3):189-198.
11. Wang H, Wang S, Liao Z, Zhao P, Su W, Niu R*, Chang J: Folate-targeting magnetic core-shell nanocarriers for selective drug release and imaging. International journal of pharmaceutics 2012, 430(1-2):342-349.
12. Han J, Zhang F, Yu M, Zhao P, Ji W, Zhang H, Wu B, Wang Y, Niu R*: RNA interference-mediated silencing of NANOG reduces cell proliferation and induces G0/G1 cell cycle arrest in breast cancer cells. Cancer Lett 2012, 321(1):80-88.
博士生導(dǎo)師：李祥春
天津醫(yī)科大學(xué)腫瘤醫(yī)院腫瘤研究所
公共實驗室
研究員，教授,，博士生導(dǎo)師
2016年畢業(yè)于香港中文大學(xué),，生物信息學(xué)方向，長期從事腫瘤基因組二代測序數(shù)據(jù)分析和挖掘工作的研究,，對腫瘤基因組學(xué)前沿研究方法和思路有深刻理解,。熟練掌握腫瘤基因分析技術(shù)方法：數(shù)據(jù)比對、突變檢測,、結(jié)構(gòu)變異分析,、腫瘤異質(zhì)性分析、突變特征圖譜分析,、驅(qū)動基因篩選,、分子分型和標(biāo)記物篩選和新抗原分析等。近5年來在國際權(quán)威刊物（Nature,、Gut,、PNAS、Nature Communications,、Cancer Research和Molecular Biology and Evolution等）上以第一作者身份共發(fā)表SCI論文8篇,，截止到目前為止一共發(fā)表近20篇SCI論文�,！�
近5年發(fā)表SCI論文：
1. Xiangchun Li, MY Wang, Meng Yang, Hongji Dai, Baifeng Zhang, Wei Wang, Xinlei Chu, Xin Wang, Hong Zheng, RuifangNiu, Kexin Chen. A mutational signature associated with alcohol consumption and prognostically significantly mutated driver genes in esophageal squamous cell carcinoma. Annals of Oncology. 2018 Jan 16. (IF: 11.855)
2. William K.K. Wu, Xiangchun Li, Xiansong Wang, Rudin Z.W. Dai, Alfred S.L. Cheng, Maggie H.T. Wang, Thomas Kwong, Tai C. Chow, Jun Yu, Matthew T.V. Chan, S. H. W. Oncogenes without a neighboring tumor-suppressor gene are more prone to amplification. MolBiolEvol. (2017). doi:10.1093 (IF: 13)
3. Li, Xiangchun, Wu, W. K. K., Xing, R., Wong, S. H., & Liu, Y. (2016). Distinct subtypes of gastric cancer defined by molecular characterization include novel mutational signatures with prognostic capability, Cancer Research, 76(7), 1724–1733. doi:10.1158/0008-5472.CAN-15-2443 (IF: 9.329)
4. Nakatsu, G., Li, Xiangchun, Zhou, H., Sheng, J., Wong, S. H., Wu, W. K. K., ... Sung, J. J. Y. (2015). Gut mucosal microbiome across stages of colorectal carcinogenesis. Nature Communications, 6, 8727. doi:10.1038/ncomms9727 (IF: 11.47)
5. Chen, K., Yang, D., Li, Xiangchun, Sun, B., Song, F., Cao, W., ... Gao, Z. (2015). Mutational landscape of gastric adenocarcinoma in Chinese: Implications for prognosis and therapy. Proceedings of the National Academy of Sciences, 6(1), 1–6. doi:10.1073/pnas.1422640112 (IF: 9.674)
6. Song, Y., Li, L., Ou, Y., Gao, Z., Li, E., Li,Xiangchun, ... Zhan, Q. (2014). Identification of genomic alterations in oesophageal squamous cell cancer. Nature, 509(7498), 91–5. doi:10.1038/nature13176 (IF: 41.456)
7. Yu, J., Wu, W. K. K., Li, Xiangchun, X. X., He, J., Li, X.-X. X., Ng, S. S. M., ... Sung, J. J. Y. (2015). Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer. Gut, 64(4), 636–45. doi:10.1136/gutjnl- 2013-306620 (IF: 14.66)
8. Song, F., Li,Xiangchun, Song, F., Zhao, Y., & Li, H. (2015). Comparative genomic analysis reveals bilateral breast cancers are genetically independent. Oncotarget. doi:10.18632/oncotarget.5569 (IF: 6.359)
9. Li, C., Gao, Z., Li, F., Li, Xiangchun, Sun, Y., Wang, M. M., ... Wei, Q. (2015). Whole Exome Sequencing Identifies Frequent Somatic Mutations in Cell-Cell Adhesion Genes in Chinese Patients with Lung Squamous Cell Carcinoma. Scientific Reports, 5(August), 14237. doi:10.1038/srep14237 (IF: 5.578)
10. Cao, Y., He, M., Gao, Z., Peng, Y., ...Li, Xiangchun, ... Ning, G. (2014). Activating hotspot L205R mutation in PRKACA and adrenal Cushing’s syndrome. Science, 344(6186), 913–7. doi:10.1126/science.1249480 (IF: 33.611)
11.Zhang, L., Zhou, Y., Cheng, C., Cui, H., Cheng, ...Li, Xiangchun, ... Cui, Y. (2015). Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. American Journal of Human Genetics, 96(4), 597–611. doi:10.1016/j.ajhg.2015.02.017 (IF: 10.931)
12.Yu, C., Yu, J., Yao, X., Wu, W. K. K., Lu, Y., ... Li,Xiangchun, ... Wang, J. J. (2014). Discovery of biclonal origin and a novel oncogene SLC12A5 in colon cancer by single-cell sequencing. Cell Research, 24(6), 701–12. doi:10.1038/cr.2014.43 (IF: 12.413)
13.Zhao, Y., Yang, J., Chen, Z., Gao, Z., Zhou, F., Li, Xiangchun, ... He, J. (2014). Identification of somatic alterations in stage I lung adenocarcinomas by next- generation sequencing. Genes Chromosomes and Cancer, 53(4), 289–298. doi:10.1002/gcc.22138 (IF: 4.041)
14.Xu, L., Li, X. X., Cai, M., Chen, J., Li, X. X., Wu, W. K. K., ...Li, Xiangchun, ... Yu, J. (2015). Increased expression of Solute carrier family 12 member 5 via gene amplification contributes to tumour progression and metastasis and associates with poor survival in colorectal cancer. Gut, 1–12. doi:10.1136/gutjnl-2014-308257 (IF: 14.66)
15.Liu, L., Xu, Y., He, M., Zhang, M., Cui, F., Lu, L., ...Li, Xiangchun, ... Esteban, M. A. (2014). Transcriptional pause release is a rate-limiting step for somatic cell reprogramming. Cell Stem Cell, 15(5), 574–588. doi:10.1016/j.stem.2014.09.018 (IF: 22.268)
16.Cheng, C., Zhou, Y., Li, H., Xiong, T., Li, S., Bi, Y., ... Li, Xiangchun, ... Cui, Y. (2016). Whole-Genome Sequencing Reveals Diverse Models of Structural Variations in Esophageal Squamous Cell Carcinoma. The American Journal of Human Genetics, 1–19. doi:10.1016/j.ajhg.2015.12.013 (IF: 10.931)
17.Tsang, D. P. F., Wu, W. K. K., Kang, W., Lee, Y.-Y., Wu, F., Yu, Z., ... Li, Xiangchun, ... Cheng, A. S. L. (2016). Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates Nuclear Factor-κB in hepatocellular carcinoma. The Journal of Pathology. doi:10.1002/path.4688 (IF: 7.429)
18.Tang, S., Wu, W. K. K., Li, Xiangchun, Wong, S. H., Wong, N., Chan, M. T. V., ... Yu, J. (2016). Stratification of Digestive Cancers with Different Pathological Features and Survival Outcomes by MicroRNA Expression. Scientific Reports, 6(4), 24466. doi:10.1038/srep24466 (IF: 5.578)
碩士生導(dǎo)師：張飛
天津醫(yī)科大學(xué)腫瘤醫(yī)院腫瘤研究所
公共實驗室
副研究員,、碩士研究生導(dǎo)師
2004年畢業(yè)于新鄉(xiāng)醫(yī)學(xué)院臨床醫(yī)學(xué)專業(yè),，2007年獲得天津醫(yī)科大學(xué)生物化學(xué)與分子生物學(xué)碩士學(xué)位,，2013年獲得天津醫(yī)科大學(xué)腫瘤學(xué)博士學(xué)位,。2008-2009曾在香港科技大學(xué)生物化學(xué)系進(jìn)修。2015年獲“天津市創(chuàng)新人才推進(jìn)計劃-青年科技優(yōu)秀人才”稱號,，2015年獲得天津市優(yōu)秀博士論文,，2016年獲得第9屆中國腫瘤學(xué)術(shù)大會優(yōu)秀論文一等獎，2017年入選天津市“131”創(chuàng)新型人才第二層次,，并獲得天津醫(yī)科大學(xué)腫瘤醫(yī)院首批“青年創(chuàng)新人才”稱號,；發(fā)表SCI收錄論文15篇，主持國家自然科學(xué)基金項目2項,，天津市科委課題2項,，天津市教委課題1項。
研究方向：
- 基于蛋白質(zhì)組學(xué)和高通量測序等研究方法篩選和鑒定與腫瘤發(fā)生發(fā)展密切相關(guān)的蛋白質(zhì),，并解析相應(yīng)的信號傳導(dǎo)網(wǎng)絡(luò),。
- 聚焦腫瘤多藥耐藥的機(jī)制研究，探索導(dǎo)致耐藥腫瘤侵襲轉(zhuǎn)移能力增強(qiáng)的分子機(jī)制,，為臨床耐藥腫瘤的治療提供新思路,。
- 研究癌細(xì)胞侵襲轉(zhuǎn)移的分子機(jī)制，解析調(diào)控癌細(xì)胞侵襲轉(zhuǎn)移的關(guān)鍵信號通路,，為臨床轉(zhuǎn)移腫瘤的治療提供新靶點,。
近年來主持的研究項目：
- 國家自然科學(xué)基金面上項目（2015/01-2018/12）：P-glycoprotein與Rack1和Src相互作用并促進(jìn)耐藥乳腺癌細(xì)胞侵襲轉(zhuǎn)移的分子機(jī)制研究（81472474，85萬元）
- 天津市自然科學(xué)基金（2016/04-2019/03）：Her3表達(dá)上調(diào)促進(jìn)耐藥乳腺癌細(xì)胞侵襲的作用機(jī)制研究（16JCYBJC25400,，10萬元）
- 天津市自然科學(xué)基金（2012/04-2015/03）：mTORC2調(diào)節(jié)TGFbeta誘導(dǎo)肺癌細(xì)胞發(fā)生EMT的分子機(jī)制研究,，編號：（12JCQNJC07000，8萬元）
- 國家自然科學(xué)基金面上項目（2011/01-2013/12）：p32在調(diào)控PKCzeta活性和乳腺癌細(xì)胞趨化運動的作用機(jī)制研究（81001188,，20萬元）
- 天津醫(yī)科大學(xué)腫瘤醫(yī)院青年創(chuàng)新優(yōu)秀人才基金（2016/10-2021/10）：多藥耐藥促進(jìn)腫瘤轉(zhuǎn)移的分子機(jī)制（30萬元）
近年來發(fā)表SCI論文(*通訊作者)：
1. Zhao Y, Ma J, Fan Y, Wang Z, Tian R, Ji W, Zhang F*, Niu R*: TGF-beta transactivates EGFR and facilitates breast cancer migration and invasion through canonical Smad3 and ERK/Sp1 signaling pathways. Molecular oncology 2018, 12(3):305-321.
2. Yuan J, Yang Y, Gao Z, Wang Z, Ji W, Song W, Zhang F*, Niu R*: Tyr23 phosphorylation of Anxa2 enhances STAT3 activation and promotes proliferation and invasion of breast cancer cells. Breast Cancer Res Treat 2017, 164(2):327-340.
3. Sun X, Zhang J, Wang Z, Ji W, Tian R, Zhang F*, Niu R*: Shp2 Plays a Critical Role in IL-6-Induced EMT in Breast Cancer Cells. International journal of molecular sciences 2017, 18(2).
4. Zhang F, Wang Z, Yuan J, Wei X, Tian R, Niu R*: RNAi-mediated silencing of Anxa2 inhibits breast cancer cell proliferation by downregulating cyclin D1 in STAT3-dependent pathway. Breast Cancer Res Treat 2015, 153(2):263-275.
5. Zhang F, Wang Z, Fan Y, Xu Q, Ji W, Tian R, Niu R*: Elevated STAT3 Signaling-Mediated Upregulation of MMP-2/9 Confers Enhanced Invasion Ability in Multidrug-Resistant Breast Cancer Cells. International journal of molecular sciences 2015, 16(10):24772-24790.
6. Zhang F, Liu Y, Wang Z, Sun X, Yuan J, Wang T, Tian R, Ji W, Yu M, Zhao Y,Niu R*:A novel Anxa2-interacting protein Ebp1 inhibits cancer proliferation and invasion by suppressing Anxa2 protein level. Mol Cell Endocrinol 2015, 411:75-85.
7. Zhang F, Zhang H, Wang Z, Yu M, Tian R, Ji W, Yang Y, Niu R*: P-glycoprotein associates with Anxa2 and promotes invasion in multidrug resistant breast cancer cells. Biochem Pharmacol 2014, 87(2):292-302.
8. Han J, Zhang F, Yu M, Zhao P, Ji W, Zhang H, Wu B, Wang Y, Niu R: RNA interference-mediated silencing of NANOG reduces cell proliferation and induces G0/G1 cell cycle arrest in breast cancer cells. Cancer Lett 2012, 321(1):80-88.
9. Zhang F, Zhang X, Li M, Chen P, Zhang B, Guo H, Cao W, Wei X, Cao X, Hao X et al: mTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis. Cancer Res 2010, 70(22):9360-9370.
10. Zhang F, Zhang L, Zhang B, Wei X, Yang Y, Qi RZ, Ying G, Zhang N, Niu R: Anxa2 plays a critical role in enhanced invasiveness of the multidrug resistant human breast cancer cells. J Proteome Res 2009, 8(11):5041-5047.
|
